hereinafter , one embodiment of the present invention is described with reference to the drawings . fig1 to 5 show a gasket 50 for a bypass type prefilled syringe according to the one embodiment of the present invention . in this bypass type prefilled syringe , powdery medicament p and pharmaceutical liquid l are , respectively , stored in a front compartment 6 and a rear compartment 7 of a tubular body 1 beforehand so as to interpose the gasket 50 therebetween , while a marked line 1 b indicative of a position for temporarily stopping a front end of the gasket 50 at the time of communication between the front and rear compartments 6 and 7 via a bypass 1 a is drawn forwardly of the bypass 1 a as shown in fig1 . since other constructions of the bypass type prefilled syringe are similar to those of a prior art bypass type prefilled syringe shown in fig6 and 7 in which a first sealing member 3 and a second sealing member 4 are provided and an injection needle 10 is mounted on a front end portion of the tubular body 1 , the description is abbreviated for the sake of brevity . fig1 and 2 show a sealing state and a communication state between the front and rear compartments 6 and 7 of the tubular body 1 , respectively . as shown in fig1 and 2 , the gasket 50 is constituted by a front gasket segment 51 and a rear gasket segment 52 which are disposed so as to abut on each other . however , the gasket 50 is not required to be constituted by the two components but may also be formed by the single front gasket segment 51 only . in this case , the bypass 1 a should be set at a small dimension in conformity with the front gasket segment 51 . the gasket 50 is made of elastomer such as synthetic rubber . fig3 a , 3 b and 3 c are a left side elevational view , a front elevational view and a right side elevational view of the front gasket segment 51 , respectively , while fig4 a , 4 b and 4 c are sectional views taken along the lines iva — iva , ivb — ivb and ivc — ivc in fig3 b , respectively . the front gasket segment 51 has a front end face 51 a and a rear end face 51 b each having four projections 72 and includes circumferential ribs 54 , 55 , 56 , 57 and 58 arranged sequentially from the front end face 51 a towards the rear end face 51 b . the front gasket segment 51 further has an annular recess 59 formed between the circumferential ribs 54 and 55 , an annular recess 60 formed between the circumferential ribs 55 and 56 , an annular recess 61 formed between the circumferential ribs 56 and 57 and an annular recess 62 formed between the circumferential ribs 57 and 58 . meanwhile , an axial rib 63 is provided at each of four circumferential positions of the annular recess 60 . likewise , an axial rib 64 is provided at each of four circumferential positions of the annular recess 61 and an axial rib 65 is provided at each of four circumferential positions of the annular recess 62 . at the time of communication between the front and rear compartments 6 and 7 , the axial ribs 63 , 64 and 65 intercept the pharmaceutical liquid l flowing in the annular recesses 60 , 61 and 62 so as to prevent the pharmaceutical liquid l from flowing through the annular recesses 60 , 61 and 62 , respectively such that the pharmaceutical liquid l in the annular recesses 60 , 61 and 62 is carried forwardly . furthermore , two semicircular axial slots 70 are , respectively , formed at diametrically opposite ends of the circumferential rib 54 and extend through the circumferential rib 54 and the annular recess 59 so as to open to the front end face 51 a . on the other hand , four axial slots 71 are , respectively , formed at circumferential positions of the circumferential rib 55 deviating from the axial slots 70 so as to bring the annular recesses 59 and 60 into communication with each other . as will been seen from fig3 a and 4a , a cross - sectional area of a flow path of the axial slot 70 is set to be larger than that of the axial slot 71 . by setting an outside diameter d 1 of the circumferential ribs 54 and 55 adjacent to the front end face 51 a to be equal to or larger than an inside diameter of the tubular body 1 but smaller than an outside diameter d 2 of the circumferential ribs 56 , 57 and 58 , the gasket 50 can be advanced smoothly while a sealing state between the tubular body 1 and the gasket 50 is being secured . meanwhile , an outside diameter of the annular recesses 59 and 60 is also set to be smaller than that of the annular recesses 61 and 62 . fig5 shows the rear gasket segment 52 . the rear gasket segment 52 has a front end face 52 a and a rear end face 52 b each having four projections 88 in the same manner as the front gasket segment 51 and includes circumferential ribs 81 , 82 and 83 which are arranged sequentially from the front end face 52 a towards the rear end face 52 b . the rear gasket segment 52 further has an annular recess 84 formed between the circumferential ribs 81 and 82 and an annular recess 85 formed between the circumferential ribs 82 and 83 . meanwhile , in the same manner as the front gasket segment 51 , an axial rib 86 is provided at each of four circumferential positions of the annular recess 84 and an axial rib 87 is provided at each of four circumferential positions of the annular recess 85 . at the time of communication between the front and rear compartments 6 and 7 , the axial ribs 86 and 87 intercept the pharmaceutical liquid l flowing in the annular recesses 84 and 85 so as to prevent the pharmaceutical liquid l from flowing through the annular recesses 84 and 85 . at the time of communication between the front and rear compartments 6 and 7 by way of the bypass 1 a , the gasket 50 is advanced by a plunger rod ( not shown ) until the front end face 51 a of the front gasket segment 51 reaches the marked line 1 b of fig1 . at this time , as shown in fig2 a gap is defined between a rear end portion of the rear gasket segment 52 and a rear end portion of the bypass 1 a , while a front end portion of the front gasket segment 51 is disposed forwardly of a front end portion of the bypass 1 a such that the tubular body 1 at a front end side of the bypass 1 a is closed by the front end portion of the front gasket segment 51 . thus , the pharmaceutical liquid l fed under pressure into the gap between the bypass 1 a and the gasket 50 as shown by the arrow b in fig2 is initially introduced into the annular recesses 84 and 85 of the rear gasket segment 52 and the annular recesses 60 to 62 of the front gasket segment 51 but is intercepted by the axial ribs 86 and 87 of the rear gasket segment 52 and the axial ribs 63 to 65 of the front gasket segment 51 so as to be delivered forwardly . then , as shown by the arrow c , the pharmaceutical liquid l is carried into the powdery medicament p along a u - shaped outflow path proceeding from the annular recess 60 to the axial slots 70 through the axial slots 71 and the annular recess 59 . this outflow path of the pharmaceutical liquid l is not restricted to the u - shaped configuration but may have an arbitrary bent shape , for example , a v - shaped configuration or an s - shaped configuration . meanwhile , in the above described embodiment , the gasket 50 is applied to the bypass type prefilled syringe of a construction having an injection needle mounted on the front end portion of the tubular body 1 but is not restricted to the bypass type prefilled syringe of this construction . the gasket 50 may also be applied to a bypass type prefilled syringe of other constructions , e . g ., a construction in which a distal end cap is mounted on a distal end of the tubular body 1 as shown in fig8 . furthermore , in the above described embodiment , the powdery medicament p and the pharmaceutical liquid l are , respectively , preliminarily stored in the front and rear compartments 6 and 7 . however , in the two components stored in the front and rear compartments 6 and 7 , respectively , at least the component stored in the rear compartment 7 should be liquid and thus , the two components may be liquid . meanwhile , in case only one of the two components is liquid , it is desirable that the other component is of simply dissoluble or dispersible dosage forms such as powder and solid medicine obtained by freeze - drying . the dosage forms include sustained release drug . for example , microsphere or the like may be recited as the sustained release drug . the microsphere includes microcapsule , microparticle , etc . more specifically , the microspheres or the microcapsules described in japanese patent laid - open publication nos . 60 - 100516 ( 1985 ), 62 - 201816 ( 1987 ), 02 - 124814 ( 1990 ), 04 - 321622 ( 1992 ), 05 - 112468 ( 1993 ), 05 - 194200 ( 1993 ), 06 - 293636 ( 1994 ), 06 - 145046 ( 1994 ), 06 - 192068 ( 1994 ), 08 - 169818 ( 1996 ), 09 - 132524 ( 1997 ), 09 - 221417 ( 1997 ) and 09 - 221418 ( 1997 ) are employed . as injections composed of the above two components , which can be administered by the two - compartment type prefilled syringe , i . e ., biologically active substances , it is possible to specify , for example , biologically active peptide , antineoplastic agent , antibiotic , antipyretic , analgesic , antiphologistic , antitussive expectorant , sedative , muscle relaxant , antiepileptic , antiulcer agent , antidepressant , antiallergic agent , cardiotonic , antiarrhythmic drug , vasodilator , hypotensive diuretic , diabetic drug , antilipemic agent , anticoagulant , hemostatic , antituberculosis drug , hormone drug , narcotic antagonist , bone resorption inhibitor , osteoplasty accelerator , angiogenesis inhibitor , etc . however , it is needless to say that the injections are not restricted to these substances . biologically active peptides are desirable as the biologically active substances . for example , biologically active peptide having a molecular weight of about 300 to 40 , 000 , desirably about 400 to 30 , 000 and more desirably about 500 to 20 , 000 may be employed . such biologically active peptide desirably has a basic group capable of forming a salt with , for example , weak acid having a pka of not less than 4 . 0 including carbonic acid , acidic bicarbonate , boric acid and lower alkane monocarboxylic acid having 1 to 3 carbon atoms . meanwhile , in place of the basic group , the biologically active peptide may also have a free acidic group or an acidic group forming a salt . hormonal action can be recited as a typical activity of the biologically active peptides . meanwhile , the biologically active peptides may be any one of a natural product , a synthetic , a semisynthetic product and a product of genetic engineering , or an analogue and / or a derivative thereof . action of these biologically active peptides may be either agonistic or antagonistic . the biologically active peptides may include luteinizing hormone releasing agent ( lh - rh ) referred also to as “ gonadotropin releasing agent ( gn - rh )”, insulin , somatostatin , somatostatin derivative such as sandostatin in u . s . pat . nos . 4 , 087 , 390 , 4 , 093 , 574 , 4 , 100 , 117 and 4 , 253 , 998 , growth hormone ( gh ) in japanese patent laid - open publication nos . 7 - 1018778 ( 1995 ) and 10 - 265404 ( 1998 ), growth hormone releasing hormone ( gh - rh ), prolactin , erythropoietin ( epo ), adrenocorticotropic hormone ( acth ), acth derivative such as ebiratide , melanocyte - stimulating hormone ( msh ), thyrotropin releasing hormone (( pyr ) glu - his - pronh2 ; trh ), a salt and a derivative thereof in japanese patent laid - open publication nos . 50 - 121273 ( 1975 ) and 52 - 116465 ( 1977 ), thyroid stimulating hormone ( tsh ), luteinizing hormone ( lh ), follicle stimulating hormone ( fsh ), vasopressin , vasopressin derivative such as desmopressin , oxytocin , calcitonin , glucagon , gastrin , secretin , pancreozymin , cholecystokinin , angiotensin , human placental lactogen , human chorionic gonadotropin ( hcg ), enkephalin , enkephalin derivative in u . s . pat . no . 4 , 277 , 394 and ep - 31567 - a , endorphin , kyotorphin , interferons such as interferon - α , interferon - β and interferon - γ , interleukins such as interleukins 1 to 12 , taftsin , thymopoietin , thymosin , thymostimulin , thymic humoral factor ( thf ), scrum thymic factor ( fts ) and its derivative in u . s . pat . no . 4 , 229 , 438 , tumor necrosis factor ( tnf ), colony stimulating factor ( csf , gcsf , gmcsf and mcsf ), motilin , dinorphin , bombesin , neurotensin , cerulein , bradykinin , atrial natriuretic factor , nerve growth factor ( ngf ), cell growth factors such as egf , tgf - β , pdgf , acidic fgf and basic fgf , neurotrophic factors such as nt - 3 , nt4 , cntf , gdnf and bdnf , peptide having endothelin antagonism and its analogue ( derivative ) in ep - 436189 - a , ep - 457195 - a , ep - 496452 - a and japanese patent laid - open publication nos . 3 - 94692 ( 1991 ) and 3 - 130299 ( 1991 ), insulin receptor , insulin - like growth factor ( igf )- 1 receptor , igf - 2 receptor , transferrin receptor , epidermal growth factor , low density lipoprotein ( ldl ) receptor , macrophage scavenger receptor , glut - 4 transporter , growth hormone receptor , peptide derived from α1 domain of major histocompatibility class i antigen complex ( mhc - i ) having activity for hampering endogeny of leptin receptor (“ proceedings of the national academy of sciences of the united states of america ”, vol . 91 , p . p . 9086 - 9090 ( 1994 ) and vol . 94 , p . p . 11692 - 11697 ( 1997 )) and its analogue ( derivative ), and a fragment or a fragment derivative thereof . in case the biologically active peptide is a salt , a pharmacologically acceptable salt or the like may be used . for example , in case the biologically active peptide has a basic group such as an amino group in its molecule , salts formed by the basic group and inorganic acids such as hydrochloric acid , sulfuric acid , nitric acid and boric acid or organic acids such as carbonic acid , acidic bicarbonate , succinic acid , acetic acid , propionic acid and trifluoroacetic acid may be used . meanwhile , in case the biologically active peptide has an acidic group such as a carboxyl group in its molecule , salts formed by the acidic group and inorganic bases including alkaline metals such as sodium and potassium and alkaline earth metals such as calcium and magnesium or organic bases including organic amines such as triethylamine and basic amino acids such as arginine may be used . furthermore , the biologically active peptide may form metal complex compounds such as a copper complex and a zinc complex . as concrete examples of the biologically active peptides desirable for use , it is possible to recite an lh - rh analogue and its salt effective for contraception and diseases dependent on either lh - rh of prostatic cancer , prostatic hypertrophy , endometriosis , myoma of the uterus , fibroma of the uterus , precocious puberty and breast cancer or a hormone derived from the lh - rh as well as a somatostatin derivative and its salt effective for diseases dependent on growth hormone and a hormone derived from the growth hormone and diseases of the digestive system such as peptic ulcer . concrete examples of the lh - rh analogue and its salt may include peptides described in “ treatment with gnrh analogs : controversies and perspectives ” published in 1966 by the parthenon publishing group ltd ., japanese patent national publication no . 3 - 503165 ( 1991 ) and japanese patent laid - open publication nos . 3 - 101695 ( 1991 ), 7 - 97334 ( 1995 ) and 8 - 259460 ( 1996 ). as a concrete example of a biologically active peptide having lh - rh antagonism , i . e ., an lh - rh antagonist , a biologically active peptide expressed by the following general formula [ ia ] or its salt may be recited . in the formula , “ x ” denotes n ( 4h 2 - furoy1 ) g1y or nac , “ a ” denotes a residual group selected from nmetyr , tyr , aph ( atz ) and nmeaph ( atz ), “ b ” denotes a residual group selected from dlys ( nic ), dcit , dlys ( azaglynic ), dlys ( azaglyfur ), dharg ( et 2 ), daph ( atz ) and dhci and “ c ” denotes lys ( nisp ), arg or harg ( et 2 ). more specifically , the biologically active peptide having lh - rh antagonism , i . e ., lh - rh antagonist may be nacd2na1 - d4c1phe - d3pa1 - ser - nmetyr - dlys ( nic )- leu - lys ( nisp )- pro - da1anh 2 , n ( 4h 2 - furoy1 ) g1y - d2na1 - d4c1phe - d3pa1 - ser - nmetyr - dlys ( nic )- leu - lys ( nisp )- pro - da1anh 2 , cetrorelix , ganirelix , antarelix , detirelix , azaline , antide , ramorelix and abarelix . these peptides can be produced by the methods described in the above prior art documents or similar methods . as a concrete example of a biologically active peptide having lh - rh agonistic action , i . e ., an lh - rh agonist , a biologically active peptide expressed by the following general formula [ ib ] or its salt may be recited . in the formula , “ y ” denotes a residual group selected from dleu , da1a , dtrp , dser ( tbu ), d2na1 and dhis ( imbz1 ) and “ z ” denotes nh — c 2 h 5 or g1y - nh 2 . especially , a peptide in which “ y ” is dleu and “ z ” is nh — c 2 h 5 or its salt is suitable . these peptides can be produced by the methods described in the above prior art documents or similar methods . a concrete example of the somatostatin derivative or its salt is described in , for example , “ proceedings of the national academy of sciences of the united states of america ”, vol . 93 , p . p . 12513 - 12518 ( 1996 ) or the documents cited therein . furthermore , as a concrete example of a somatostatin derivative selectively effective for tumor in somatostatin analogues , a biologically active peptide described in u . s . pat . no . 5 , 480 , 870 or ep - 505680 - a and having the following formula may be recited . meanwhile , sandostatin in u . s . pat . nos . 4 , 087 , 390 , 4 , 093 , 574 , 4 , 100 , 117 and 4 , 253 , 998 may be suitable . in the above described biologically active peptides , 5 - oxo - pro - his - trp - ser - tyr - dleu - leu - arg - pro - nh — c 2 h 5 ( leuprorelin ) or its salt , especially , acetate is preferable . as the above biologically active substances , non - peptide drugs , etc . may be used . more specifically , compounds described in , for example , japanese patent no . 2946298 and japanese patent laid - open publication nos . 3 - 232880 ( 1991 ) and 4 - 364179 ( 1992 ) may be recited as the drugs . as is clear from the foregoing description of the gasket 50 for the bypass type prefilled syringe , according to the present invention , at the time of communication between the front and rear compartments 6 and 7 via the bypass 1 a , since the tubular body 1 at the front end side of the bypass 1 a is closed by the front end portion of the front gasket segment 51 and the pharmaceutical liquid l is introduced into the powdery medicament p along the u - shaped outflow path proceeding from the annular recess 60 to the axial slots 70 by way of the axial slots 71 and the annular recess 59 , a squirt phenomenon of the pharmaceutical liquid l is prevented positively . as a result , since the powdery medicament p is sufficiently dissolved or dispersed in the pharmaceutical liquid l , satisfactory injection liquid can be prepared at all times . meanwhile , in the gasket 50 for the bypass type prefilled syringe , according to the present invention , at the time of communication between the front and rear compartments 6 and 7 via the bypass 1 a , since the pharmaceutical liquid l carried into the annular recesses 84 and 85 of the rear gasket segment 52 and the annular recesses 60 to 62 of the front gasket segment 51 is intercepted by the axial ribs 86 and 87 and the axial ribs 63 to 65 , respectively so as to be delivered forwardly , the pharmaceutical liquid l is efficiently introduced into the powdery medicament p without incurring such a loss that the pharmaceutical liquid l remains in the annular recesses 84 and 85 of the rear gasket segment 52 and the annular recesses 60 to 62 of the front gasket segment 51 for a long time . furthermore , in the gasket 50 for the bypass type prefilled syringe , according to the present invention , since the cross - sectional area of the flow path of the axial slot 70 opening to the front end face 51 a of the front gasket segment 51 is set to be larger than that of the axial slot 71 formed on the circumferential rib 55 , delivery speed of the pharmaceutical liquid l in the axial slots 70 drops below that of the pharmaceutical liquid l in the axial slots 71 in the u - shaped outflow path at the time of communication between the front and rear compartments 6 and 7 via the bypass 1 a , so that the squirt phenomenon of the pharmaceutical liquid is prevented more positively . in addition , in the gasket for the bypass type prefilled syringe , according to the present invention , since the outside diameter d 1 of the circumferential ribs 54 and 55 is set to be equal to or larger than the inside diameter of the tubular body 1 but smaller than the outside diameter d 2 of the circumferential ribs 56 to 58 , the small - diameter circumferential ribs 54 and 55 are lightly fitted into the tubular body 1 forwardly of the bypass 1 a at the time of communication between the front and rear compartments 6 and 7 via the bypass 1 a , so that an operation of advancing the front end of the gasket 50 to the marked line 1 b can be performed smoothly .
a bypass type prefilled syringe has a tubular body formed with a bypass for establishing communication between front and rear compartments for preliminarily storing medicament and pharmaceutical liquid , respectively . a gasket for dividing interior space of the tubular body into the front and rear compartments includes a plurality of circumferential ribs . a plurality of annular recesses are each formed between neighboring ones of the circumferential ribs . first and second axial slots are formed on the circumferential ribs so as to define a bent outflow path for the pharmaceutical liquid at the time of communication between the front and rear compartments via the bypass .